SR One Capital Management
Simeon is CEO of SR One, with overall responsibility for the fund and is Chair of the Investment Committee. Simeon joined SR One in 2007 and established its San Francisco office in 2010. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.
SR One Capital Management
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies.